Peptides corresponding to various regions of type I rat transforming growth factor (rTGF) have been chem-
immunize rabbits. An antiserum raised against one of these peptides, corresponding to the carboxyl-terminal 17 amino acids of rTGF, has been used to develop a competitive RIA for the immunizing peptide. In this assay, the antiserum reacts only with a restricted region of the immunizing peptide corresponding to the 11 carboxyl-terminal amino acids of the rTGF molecule. Intact rTGF competes as well as the immunizing peptide on a molar basis, indicating that the cognate sequence in rTGF is recognized by this antiserum. Mouse epidermal growth factor (mEGF) was ineffective as a competitor, even at a 10,000-fold greater concentration, showing that the RIA was capable of distinguishing TGF from functionally related proteins. Several immunoreactive species were detected by gel filtration of conditioned medium from cultured retrovirus-transformed rat cells; both a low molecular weight species that corresponds to rTGF, and a higher molecular weight specie(s) copurify with biologic activity in the EGF radioreceptor assay. Immunoblotting analysis of the higher molecular weight peak fractions revealed three polypeptides (M$, 24,000, 40,000, and 42,000) that reacted specifically with the antiserum. These findings suggest the existence of a family of larger polypeptides containing both structural and functional determinants of rTGF.
Certain retrovirus-transformed rodent cells and some human tumor lines release into their culture medium powerful growth-promoting peptides, termed transforming growth factors (TGFs) (1) . Two classes of TGF have been identified: type I TGFs, which compete with epidermal growth factor (EGF) for binding to its receptor (2) ; and type II TGFs, which apparently potentiate the biologic activity of type I TGFs, but do not themselves bind to the EGF receptor (3) . Partial amino acid sequences of type I TGFs from rodent and human sources (4) and the complete sequence of rat TGF (rTGF) (5) have been reported.
Although much is now known regarding the chemical properties of type I TGFs and their biologic properties in vitro, the role of these factors in development of the malignant state in vivo remains unclear. This uncertainty stems in part from the difficulties in detecting these factors. TGFs have been detected previously with biologic assays, and while these are quite sensitive, they do not readily distin, guish between TGFs and other related biologically active molecules in impure preparations.
In this report, we describe the development of immunologic reagents for type I TGF. We have produced antibodies capable of recognizing rTGF by immunizing animals with synthetic peptides corresponding to different regions of the molecule. One of these antisera was used to study the relationship between different size classes of TGFs secreted by cultured tumor cell lines. Chromatography. Gel filtration chromatography was performed on columns of Bio-Gel P-10 (Bio-Rad) equilibrated in 1 M acetic acid. HPLC was carried out on a Novapak C18 column (0.39 x 10 cm; Waters Associates), using a flow rate of 1 ml/min at 230C.
MATERIALS AND METHODS
Preparation of Conditioned Medium. Serum-free conditioned medium from Snyder-Theilen-transformed Fischer rat embryo cells (ST-FeSV-FRE clone-10) was collected as described (8) . The medium was clarified by low-speed centrifugation and lyophilized. The residue was then resuspended in 1 M acetic acid and dialyzed extensively against 0.1 M acetic acid. Insoluble protein was removed by centrifugation and the supernatant was lyophilized. Finally, the residue was resuspended in 100th the original volume of 1 M acetic acid 4nd stored at 40C.
Immunoblotting Analysis. Samples to be analyzed were first subjected to NaDodSO4/PAGE on a 15%-20% acrylamide gradient, run under reducing conditions, using the system described by Laemmli (9) . After separation, proteins were electrophoretically transferred to nitrocellulose (Schleicher & Schuell, BA85, 0.45 u) as described by Burnette (40). Transfer was accomplished at -5 V/cm for a period of 3-4 hr at 23°C. The resulting protein blot was incubated overnight in a milk-based cocktail, BLOTTO (11). Antiserum was diluted in BLOTTO and added to the blot in the presence or absence of excess peptide III. Incubation with antibody was continued with frequent agitation for 2-3 hr at 23°C. The blot was then washed and incubated with 125I-labeled protein A (4 x 106 cpm/ml; 4 x 107cpm/,ug) for 1 hr at 23°C, and washed with BLOTTO. Antibody binding sites were visualized after autoradiography on Kodak XAR-5 film at -70°C using intensifying screens.
RESULTS
Production of Anti-peptide Antisera. The complete amino acid sequence of rTGF is shown in Fig. 1 (5) . Synthetic peptides corresponding to various regions of native rTGF were synthesized, conjugated to carrier protein, and used as immunogens. The production of antibodies specific for the immunizing peptide was monitored with a solid phase enzymelinked immunoabsorbent assay. Serum from one rabbit immunized with peptide III was used for further study; the immunoglobulin fraction of this serum was used in all subsequent experiments.
Radioimmunoassay for rTGF Peptide. We wished to use this antiserum as the basis for a sensitive and quantitative assay for rTGF. Since this factor was unavailable in quantities sufficient for use as an assay standard, we decided to use the immunogen (peptide III) as a basis for an assay.
Binding of a radioiodinated derivative of peptide III to antibody was measured after separation of antigen-antibody complexes with formalin-fixed S. aureus. Using this RIA, 0.6 pmol of 125I-labeled peptide III was quantitatively precipitated with a 1:10 dilution of antisera; measurable radioactivity was precipitated even at a dilution of >10,000. Antibody affinity was measured by incubating the antiserum at a final dilution of 1:5000 with various concentrations of 125I-labeled peptide III. Analysis of these data by the method of Scatchard (12) Specificity of Radioimmunoassay. To determine the specificity of the radioimmunoassay, we tested various peptides for their ability to inhibit precipitation of 125I-labeled peptide III. The experiment described in Fig. 2 shows that unlabeled peptide III inhibited the precipitation of 125I-labeled peptide III in the range of 0.13 to 11 nM; the concentration of unlabeled peptide III that produced half-maximal inhibition of precipitation was 0.7 nM. Peptide IV (corresponding to residues 41-50) was somewhat less effective an inhibitor of precipitation than was peptide III, but peptide II (residues 34-43) was totally ineffective at concentrations up to 1.1 /iM. Peptide I, corresponding to the amino-terminal 11 residues, also was ineffective as a competitor. These results indicate that the epitope detected under standard assay conditions was localized to the carboxyl-terminal 11 amino acids of peptide III. A summary of the relative inhibitory concentrations of various peptides is presented in Table 1 .
rTGF was also tested for its ability to inhibit precipitation of 125I-labeled peptide III. Fig. 3 shows that synthetic rTGF, which was indistinguishable from the native molecule in biologic activity (6), was equally as effective (on a molar basis) an inhibitor as was peptide III. The relative inhibitory capacity of rTGF was considerably diminished when a reducing agent was omitted from the reaction mixture ( Additions were tested for their ability to inhibit the standard RIA. Concentration of each addition necessary to achieve half-maximal inhibition of precipitation was determined and is expressed relative to the concentration of peptide III required to give the same level of inhibition. The symbol ">" indicates the highest concentration tested. Inhibitory activities of peptides I-IV were unaffected by inclusion of dithiothreitol in the assay. also shows that mEGF is totally ineffective as a competitor, at concentrations ranging up to >1 uM. mEGF also failed to compete in the absence of a reducing agent (data not shown).
This indicates that the RIA described here differs from other available assays for TGF in that it is specific for TGF and does not recognize even very high concentrations of EGF.
To (8) . Serum-free conditioned medium was collected, processed, and concentrated. An aliquot was then subjected to gel filtration chromatography on Biogel P-10 under acidic conditions. Fractions were analyzed for TGF by the EGF receptor competition assay or by RIA. The results of a typical experiment are shown in Fig. 4 .
Two size classes of EGF-competing activity with apparent Mrs of 10,000 and 20,000 were detected under these conditions. Both species have been identified previously (8, 13) , and have been shown to also possess soft agar growth-promoting activity. The Mr 10,000 species corresponds to the form of rTGF used for primary structure determination (13) . Both size classes of EGF-competing activity also showed immunologic activity. Additional immunologic activity was found in the excluded volume of the column in which no EGF-competing activity was detected. The ratio of EGFcompeting to immunologic activity was greatly reduced in the high molecular weight TGF fractions, indicating that the biologic activities of these TGF(s) species are less than those of the low molecular weight fractions.
To confirm that the immunologic activity shown in Fig. 4 was carried by the same molecular species as EGF-competition activity, pooled fractions containing the Mr 10,000 or Mr 20,000 size classes of rTGF were subjected to reversedphase HPLC; conditions used were similar to those used in the purification of rTGF (4). Profiles of EGF-competing and immunologic activities obtained with the Mr 10,000 TGF pooled fractions are presented in Fig. 5 . Both EGF-competing and immunologic activity were shown to copurify with essentially quantitative yields. The copurification of both activities during both gel filtration chromatography (Fig. 4) FIG. 5. Copurification of low molecular weight EGF-competing activity with immune reactive species. A large scale version of the P-10 column described in Fig. 4 was run, and fractions containing EGF-competing activity were located using the radioreceptor assay. Fractions containing Mr 10,000 TGF (corresponding to fractions 38-45 from Fig. 4) were pooled, lyophilized, and resuspended in 0.05% trifluoroacetic acid prior to analysis by HPLC. (Upper) Column was eluted with a gradient of acetonitrile (----) in 0.05% trifluoroacetic acid and absorbance at 214 nM (-) was measured. (Lower) Fractions were collected, lyophilized, and assessed for TGF activity by either the radioreceptor assay (o) or RIA (e). Recoveries of both activities were -90%. HPLC (Fig. 5 ) strongly suggests that both activities are carried by the same molecular species. When the Mr 20,000 EGF-competing activity was subjected to analysis by HPLC, a similar copurification of EGF-competing and immunologic activities was observed (Fig. 6) . These experiments show that the high molecular weight material with EGF-competing activity is antigenically, as well as functionally, related to rTGF.
Immunoblotting Analysis of Different Size Classes of rTGF.
The larger size classes of TGFs found in conditioned medium from retroviral transformed rat cells could represent either aggregated states or distinct molecular forms of the TGF molecule. To distinguish between these alternatives, we subjected synthetic rTGF and both the Mr 10, no Mr 6000 TGF was detected in the large molecular weight size class. These results demonstrate that the higher molecular weight size classes of rTGF represent distinct polypeptide chains.
DISCUSSION
Growth modulating peptides such as TGF are active at extremely low concentrations and are thus difficult to obtain in quantities sufficient to produce immunological reagents by conventional means. Synthetic peptides corresponding to defined regions of these molecules represent a convenient alternative source of immunogen. The affinity of the antibodies we have raised against synthetic peptides is relatively high, with apparent affinity constants of 8.6 x 108 M-1 for peptide III and 2.4 x 108 M-1 for rTGF. While limited information concerning affinities of synthetic peptide antibodies is available, antibodies against other antigens generally have affinity constants ranging between 105 and 1011 M-1 (14) .
Where affinity constants for synthetic peptide antibodies have been determined, the values are similar to those we have measured. Gentry et al. (15) minus of the active molecule is folded in such a way as to render it less accessible for antibody binding.
The most significant result of these studies is the demonstration that the various size classes of TGFs previously observed (8, 13) represent distinct molecular entities sharing both structural and functional determinants. This may indicate that rTGF, like many other polypeptide hormones, is synthesized as a larger molecule that is subsequently cleaved. cDNA cloning studies have shown the related polypeptide, EGF, to be synthesized as a polypeptide of Mr 128,000, a molecule some 20 times larger than EGF itself (18, 19) . Preliminary cDNA cloning studies also suggest a larger precursor for rTGF (ref. 20) . Our finding of larger secreted forms of rTGF suggests that the precursor molecule may be at least partially processed extracellularly. It is also of interest that immunologically reactive Mr 10,000 and Mr 20,000 size classes of TGF activity were also detected after gel filtration of serum-free conditioned medium from a cultivated human melanoma cell line (unpublished data). This suggests that TGF heterogeneity is not unique to the transformed rodent cells examined in the present study. Thus, elucidation of the precise relationship between the various rTGF mole-
